Hero image with Pittsburgh background pittplusme.org/study/1246

Pitt+Me UPCI 15-101


STUDY BASICS

Are you age 60 or up, are in complete remission after receiving treatment for acute myeloid leukemia (AML), but are not a candidate for stem cell transplant? If so, you may be eligible to participate in a study that is testing an investigational drug to see if can extend your remission period. Study participation involves a 30-minute intravenous infusion once every 3 weeks for up to 2 years.


IRB:
  STUDY19040090 - HCC 15-101: A Phase II study of Pembrolizumab as Post-Remission Treatment of Patients Age 60 or Older with AML Who Are Not Transplantation Candidates

Age Range
AGE:   60 and Up

Duration DURATION:  up to 2 years

Location LOCATION: 
UPMC Cancer Center
Compensation COMPENSATION: 
None
Phone Number PHONE NUMBER:
1-866-438-8230
I'M INTERESTED
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   FacebookFacebook   TwitterTwitter   Linked-InLinked-In
Search Icon pittplusme.org/study/1246
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe facebook twitter

Pitt+Me

This website is maintained by the Clinical and Translational Science Institute.
© Copyright 2018, University of Pittsburgh. All rights reserved.